Journal of photochemistry and photobiology. B, BiologySep 14, 2026

Light-controlled gene-editing nanoparticles to manage kidney scarring

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 15, 2026

Abstract

Photoresponsive renal nanomedicine offers a potential strategy for localized control of fibrotic cell states in chronic kidney disease.

Renal fibrosis is linked to complex interactions among various cell types and processes in chronic kidney disease.
Current therapies slow kidney function decline but do not directly target the underlying regulatory circuits of fibrosis.
Combining photoresponsive nanomaterials with gene regulation techniques may enable precise modulation of fibrotic gene programs.
The review discusses several types of nanomaterials, including upconversion nanoparticles and photoresponsive polymers, for targeted renal applications.
The focus is on achieving reversible regulation of gene activity rather than permanent changes to the genome.
Assessment criteria for safety and preclinical validation are outlined to support the development of this therapeutic approach.

Simplified

Renal fibrosis is the final common pathway of progressive chronic kidney disease and is maintained by spatially heterogeneous interactions among injured epithelial cells, activated fibroblasts, immune cells, extracellular matrix remodeling, metabolic stress, and persistent profibrotic transcriptional programs. Current therapies slow renal functional decline but do not directly control the regulatory circuits that stabilize maladaptive repair. Photoresponsive renal nanomedicine offers a potential strategy to add external control to anti-fibrotic intervention by combining kidney-directed delivery with light-gated release or activation of molecular payloads. This review examines the emerging interface between photoresponsive nanomaterials and CRISPR/dCas9-based gene regulation for renal fibrosis, with emphasis on upconversion nanoparticles, photoresponsive polymers, ROS- and pH-responsive matrices, optogenetic switches, and renal-compartment-directed carrier design. We argue that the most defensible therapeutic objective is not permanent genome editing or autonomous organ regeneration, but spatially confined, temporally limited, and reversible regulation of validated fibrotic or protective gene programs using CRISPRa, CRISPRi, or dCas9-based epigenome editors. The review therefore evaluates material requirements, optical-dosimetry constraints, payload architecture, renal biodistribution, target-selection logic, safety risks, and preclinical validation criteria. By defining the engineering and biological conditions required for controlled anti-fibrotic regulation, this framework positions photoresponsive renal nanomedicine as a translationally testable route toward localized modulation of fibrotic cell states rather than an overextended claim of kidney regeneration.

Full Text

Full text is available at the source.

View Full Text ↗

Light-controlled gene-editing nanoparticles to manage kidney scarring

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the crispr gene editing brief